Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusion

2002383 citationsJournal Article

Authors

Larry W. Moreland · University of Alabama at Birmingham

Rieke Alten · Schlosspark-Klinik

Filip Van den Bosch

Thierry Appelboom

Marc Léon · CHU Ambroise Paré

Paul Emery · University of Leeds

Stanley Cohen · Metroplex Clinical Research Center

Michael E. Luggen

Abstract

Both of the costimulatory blocking molecules studied were generally safe and well tolerated. As compared with placebo, both CTLA-4Ig and LEA29Y demonstrated efficacy in the treatment of RA.

Topics & Keywords

T-cell and B-cell Immunology Immune Cell Function and Interaction Monoclonal and Polyclonal Antibodies Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Arthritis & Rheumatism

Volume 46, Issue 6, pp. 1470-1479

DOI: 10.1002/art.10294

Field-Weighted Citation Impact: 7.84